Zakażenie mrsa – Leczenie

Zakażenie mrsa
Leczenie

Metycylinooporne szczepy Staphylococcus aureus (MRSA) charakteryzują się opornością na beta-laktamy, w tym metycylinę, penicyliny, cefalosporyny i oksacylinę, co komplikuje terapię zakażeń. Leczenie MRSA wymaga indywidualizacji w oparciu o lokalizację i ciężkość infekcji oraz wyniki antybiogramu. W przypadku ropni skórnych podstawą jest drenaż chirurgiczny, a antybiotykoterapia stosowana jest w zakażeniach umiarkowanych i ciężkich. Wankomycyna (15-20 mg/kg co 8-12 h, max 2 g/dawka) pozostaje lekiem pierwszego wyboru w ciężkich zakażeniach, zwłaszcza u hospitalizowanych, z monitorowaniem stężeń minimalnych (15-20 μg/ml) ze względu na nefrotoksyczność. Alternatywy to linezolid (600 mg 2x/dobę), daptomycyna (4-6 mg/kg/dobę), trimetoprim/sulfametoksazol, klindamycyna, tetracykliny oraz cefarolina. Terapie trwają od 5-14 dni w zakażeniach skóry, do 4-6 tygodni w zapaleniu wsierdzia i co najmniej 8 tygodni w osteomyelitis. W ciężkich przypadkach wskazana jest terapia skojarzona i hospitalizacja.

Zakażenie MRSA – podstawy leczenia

Metycylinooporne szczepy Staphylococcus aureus (MRSA) stanowią istotne wyzwanie terapeutyczne ze względu na oporność na wiele standardowych antybiotyków. Bakterie MRSA wykazują oporność na metycylinę oraz inne antybiotyki beta-laktamowe, takie jak penicylina, amoksycylina, cefalosporyny i oksacylina, co czyni je trudniejszymi w leczeniu¹². Mimo to, istnieje wiele skutecznych opcji terapeutycznych, które pozwalają na leczenie zakażeń MRSA. Wybór odpowiedniej terapii zależy od lokalizacji i ciężkości zakażenia, wrażliwości szczepu na antybiotyki oraz indywidualnych cech pacjenta³. Obecnie ponad połowa wszystkich przypadków zakażeń MRSA jest skutecznie leczona antybiotykami, a większość infekcji skórnych MRSA jest z powodzeniem wyleczana⁴.

Drenaż i leczenie chirurgiczne

Podstawową metodą leczenia, szczególnie w przypadku ropni skórnych i infekcji tkanek miękkich związanych z MRSA, jest drenaż chirurgiczny⁵⁴. W przypadku małych, niepowikłanych ropni, samo nacięcie i drenaż mogą być wystarczającym leczeniem, bez konieczności stosowania antybiotyków⁶⁷. Drenaż ropni powinien być wykonywany wyłącznie przez personel medyczny. Samodzielne próby oczyszczenia zakażenia mogą prowadzić do pogorszenia stanu i rozprzestrzenienia infekcji⁸.

Po drenażu konieczne jest prawidłowe opatrywanie rany – rana powinna być utrzymywana w czystości i pokryta suchym, sterylnym opatrunkiem aż do wygojenia⁸. W przypadku głębszych zakażeń lub zakażeń o charakterze ogólnoustrojowym może być konieczne bardziej rozległe leczenie chirurgiczne, w tym usunięcie martwiczych tkanek⁹.

Antybiotykoterapia w leczeniu MRSA

Antybiotyki stosowane w leczeniu MRSA

Wybór antybiotyku zależy od wyników antybiogramu, lokalizacji i ciężkości zakażenia oraz indywidualnych cech pacjenta¹⁰. Do najczęściej stosowanych antybiotyków w leczeniu zakażeń MRSA należą:

Wankomycyna – jest lekiem pierwszego wyboru w ciężkich zakażeniach MRSA, szczególnie u pacjentów hospitalizowanych¹¹¹²
Linezolid (Zyvox) – skuteczny zarówno w formie doustnej, jak i dożylnej¹³
Daptomycyna (Cubicin) – alternatywa dla wankomycyny, gdy ta nie jest dostępna lub nie jest tolerowana¹¹
Trimetoprim/sulfametoksazol (Bactrim, Septra) – często stosowany w leczeniu ambulatoryjnym¹⁴
Klindamycyna – skuteczna w przypadku niektórych szczepów MRSA¹⁵
Tetracykliny (doksycyklina, minocyklina) – opcja w leczeniu ambulatoryjnym¹⁵
Ceftarolina – cefalosporyna piątej generacji aktywna wobec MRSA¹⁶
Dalbawancyna i oritawancyna – leki długodziałające, mogą być podawane w pojedynczej dawce¹⁷
Tedizolid – nowszy lek z grupy oksazolidynonów, bardziej potentny niż linezolid¹⁷
Telawancyna – zatwierdzona do leczenia zapalenia płuc nabytego w szpitalu¹⁷
Delafloksacyna – antybiotyk z grupy fluorochinolonów³

Leczenie ambulatoryjne infekcji MRSA

W przypadku łagodnych do umiarkowanych zakażeń skóry i tkanek miękkich, które można leczyć ambulatoryjnie, najczęściej stosuje się antybiotyki doustne przez okres 7-14 dni¹⁴¹⁸. Typowe schematy leczenia obejmują:

Trimetoprim/sulfametoksazol (Bactrim DS) w dawce 160/800 mg dwa razy dziennie¹⁹
Klindamycyna 300 mg trzy razy dziennie¹⁹
Doksycyklina 100 mg dwa razy dziennie¹⁹
Minocyklina jako alternatywa dla doksycykliny¹⁹

Kluczowe jest, aby pacjent dokończył pełną zaleconą kurację antybiotykową, nawet jeśli objawy ustąpią wcześniej¹⁴. Przedwczesne zakończenie terapii może prowadzić do nawrotu infekcji lub rozwoju oporności bakterii⁶.

Leczenie szpitalne infekcji MRSA

Pacjenci z ciężkimi zakażeniami MRSA, zakażeniami ogólnoustrojowymi lub powikłaniami wymagają leczenia szpitalnego z zastosowaniem antybiotyków dożylnych²⁰. Najczęściej stosowane schematy obejmują:

Wankomycyna dożylnie w dawce 15-20 mg/kg co 8-12 godzin, nie przekraczając 2 g na dawkę²¹²²
Daptomycyna 4 mg/kg dożylnie raz dziennie w zakażeniach skóry i tkanek miękkich, 6 mg/kg raz dziennie w bakteriemii²¹
Linezolid 600 mg dożylnie (lub doustnie) dwa razy dziennie²¹
Ceftarolina 600 mg dożylnie co 12 godzin²¹

W przypadku ciężkich zakażeń często stosuje się terapię skojarzoną, podając jednocześnie więcej niż jeden antybiotyk, co pozwala na zwiększenie skuteczności leczenia⁴²³.

Monitorowanie terapii wankomycyną

Przy stosowaniu wankomycyny w leczeniu ciężkich zakażeń MRSA zaleca się monitorowanie stężenia leku w surowicy, dążąc do osiągnięcia stężeń minimalnych (trough) 15-20 μg/ml²². Wankomycyna może wykazywać nefrotoksyczność zależną od dawki, szczególnie przy utrzymywaniu wysokich stężeń minimalnych²⁴.

Leczenie specyficznych postaci zakażeń MRSA

Bakteriemia i zapalenie wsierdzia

W przypadku bakteriemii MRSA i zapalenia wsierdzia, zalecane są następujące schematy leczenia:

Niepowikłana bakteriemia: wankomycyna lub daptomycyna w dawce 6 mg/kg dożylnie raz dziennie przez co najmniej 2 tygodnie²⁵²²
Zapalenie wsierdzia: wankomycyna lub daptomycyna (6 mg/kg dożylnie raz dziennie) przez minimum 6 tygodni²⁵²⁶
W przypadku bakteriemii powikłanej i zapalenia wsierdzia, leczenie dożylne powinno trwać co najmniej 4-6 tygodni, oprócz drenażu ewentualnych ognisk septycznych²⁷

Wytyczne American Heart Association z 2015 roku zalecają dożylną wankomycynę jako leczenie pierwszego rzutu zapalenia wsierdzia. U pacjentów, którzy nie tolerują wankomycyny, należy zastosować daptomycynę²⁶.

Zapalenie płuc wywołane przez MRSA

W przypadku pozaszpitalnego zapalenia płuc o ciężkim przebiegu zaleca się empiryczne leczenie obejmujące MRSA do czasu uzyskania wyników posiewów plwociny i/lub krwi²⁵. Opcje leczenia obejmują:

Wankomycyna dożylnie¹⁶
Linezolid (doustnie lub dożylnie)¹⁶
Klindamycyna (doustnie lub dożylnie) u pacjentów z wrażliwymi szczepami²⁷

Czas trwania antybiotykoterapii w zapaleniu płuc wywołanym przez MRSA powinien wynosić od 7 do 21 dni, w zależności od odpowiedzi pacjenta²⁷.

Zakażenia kości i stawów

W leczeniu zapalenia kości i szpiku (osteomyelitis) oraz infekcji stawów wywołanych przez MRSA podstawą jest drenaż chirurgiczny i debridement zakażonych tkanek²⁵. Leczenie antybiotykami powinno trwać:

Zapalenie kości i szpiku: minimum 8 tygodni²⁸
Septyczne zapalenie stawów (niezwiązane z protezami): 3-4 tygodnie²⁷

Wybór antybiotyku zależy od wrażliwości szczepu, ale najczęściej stosuje się wankomycynę dożylnie²⁹.

Zakażenia ośrodkowego układu nerwowego

W zakażeniach ośrodkowego układu nerwowego wywołanych przez MRSA, w tym zapaleniu opon mózgowo-rdzeniowych, zaleca się:

Wankomycyna dożylnie przez 2 tygodnie²⁸
Linezolid lub trimetoprim/sulfametoksazol dożylnie jako alternatywy²²

W przypadku zakażenia związanego z zastawką komorowo-otrzewnową, zaleca się usunięcie zastawki (z wymianą dopiero po uzyskaniu jałowych posiewów płynu mózgowo-rdzeniowego) oraz antybiotykoterapię²².

Nowe podejścia w leczeniu MRSA

Leki długodziałające

Dalbawancyna i oritawancyna to nowe lipoglikopeptydowe antybiotyki o przedłużonym działaniu, które mogą być podawane raz w tygodniu lub nawet w pojedynczej dawce³⁰. Schematy dawkowania obejmują:

Dalbawancyna: schemat jednej dawki 1500 mg lub schemat dwóch dawek: początkowa dawka 1000 mg, a następnie 500 mg tydzień później²¹
Oritawancyna: 1200 mg dożylnie w pojedynczej dawce²¹

Te leki są obecnie zatwierdzone do leczenia ostrych bakteryjnych zakażeń skóry i struktur skórnych (ABSSSI), ale mają potencjał w leczeniu innych zakażeń, takich jak zapalenie kości i szpiku czy zapalenie wsierdzia³¹. Ich zaletą jest możliwość uniknięcia hospitalizacji, wcześniejszego wypisu ze szpitala lub wyeliminowania potrzeby kontynuowania pozaszpitalnej terapii parenteralnej (OPAT)³⁰.

Innowacyjne metody leczenia

Badania nad nowymi metodami leczenia MRSA obejmują:

Terapię niebieskim światłem w połączeniu z nadtlenkiem wodoru – badania wykazały, że ta metoda może zabić 99,9% bakterii MRSA bez uszkadzania zdrowych komórek³²
Nanocząsteczki magnetyczne ukierunkowane na bakterie i wspomagane mikrofalami – nowy system z możliwością precyzyjnego przechwytywania bakterii i magnetycznego ukierunkowania, połączony z synergistycznym efektem mikrofalokaloricarnego grzania i chemioterapii³³³⁴
Właściwości przeciwdrobnoustrojowe białek komórek macierzystych – wydzielina pewnego rodzaju komórek macierzystych skutecznie zmniejszała żywotność MRSA³⁵
Kombinacje trzech antybiotyków beta-laktamowych (meropenem, piperacylina i tazobaktam), które indywidualnie nie są skuteczne przeciwko MRSA, ale w połączeniu mogą niszczyć te bakterie³⁶

Te innowacyjne podejścia mogą w przyszłości zapewnić nowe opcje leczenia zakażeń MRSA, szczególnie tych opornych na dostępne obecnie antybiotyki³⁷.

Dekolonizacja MRSA

Dekolonizacja to proces mający na celu eradykację lub zmniejszenie bezobjawowego nosicielstwa MRSA, co może zmniejszyć ryzyko nawrotów zakażeń i rozprzestrzeniania się bakterii³⁸³⁹. Standardowe protokoły dekolonizacji obejmują:

Mupirocyna 2% (Bactroban) – maść do nosa, stosowana 2-3 razy dziennie przez 5 dni⁴⁰³⁹
Antyseptyczne środki do mycia ciała zawierające 4% chlorheksydynę (Hibiscrub) lub triclosan 1% – stosowane raz dziennie przez 5 dni³⁹
Antybakteryjne mydła i środki do dezynfekcji rąk⁴⁰

Dekolonizację rozważa się u pacjentów z nawracającymi zakażeniami MRSA, mimo dobrej higieny osobistej i właściwej pielęgnacji ran, lub gdy u innych domowników również rozwijają się zakażenia²⁵. Sukces dekolonizacji zależy od wielu czynników, w tym od dokładności stosowania zaleconych procedur⁴¹.

Czas trwania leczenia i monitoring

Czas trwania leczenia zakażeń MRSA zależy od rodzaju i ciężkości infekcji⁹:

Niepowikłane zakażenia skóry i tkanek miękkich: 5-14 dni¹⁸¹⁰
Bakteriemia niepowikłana: minimum 14 dni²⁵
Bakteriemia powikłana i zapalenie wsierdzia: 4-6 tygodni²⁷
Zapalenie kości i szpiku: minimum 8 tygodni²⁸
Zapalenie stawów: 3-4 tygodnie²⁷
Zapalenie opon mózgowo-rdzeniowych: 2 tygodnie²⁸

Ważne jest regularne monitorowanie pacjenta podczas leczenia. W przypadku bakteriemii MRSA zaleca się wykonanie kontrolnych posiewów krwi po 2-4 dniach od początkowego dodatniego wyniku, aby ocenić skuteczność leczenia²². U pacjentów z bakteriemią lub zapaleniem wsierdzia należy wykonać badanie echokardiograficzne w celu wykluczenia zapalenia wsierdzia oraz ocenę kliniczną w poszukiwaniu innych ognisk zakażenia²².

Pacjent powinien zgłosić się do lekarza, jeśli podczas lub po leczeniu zakażenia MRSA wystąpią nowe objawy, takie jak gorączka, która nie ustępuje, pogorszenie infekcji, brak gojenia lub nawrót zakażenia⁸.

Oporność na antybiotyki i wyzwania terapeutyczne

Pojawiają się szczepy MRSA wykazujące oporność nawet na wankomycynę i teikoplaninę. Szczepy o pośrednim poziomie oporności (4-8 μg/ml), określane jako GISA (S. aureus o pośredniej oporności na glikopeptydy) lub VISA (S. aureus o pośredniej oporności na wankomycynę), zaczęły pojawiać się pod koniec lat 90. XX wieku⁴².

Pierwszy udokumentowany szczep z całkowitą opornością na wankomycynę (≥16 μg/ml), określany jako VRSA (S. aureus oporny na wankomycynę), pojawił się w Stanach Zjednoczonych w 2002 roku⁴². Obecne wytyczne zalecają daptomycynę w leczeniu bakteriemii i zapalenia wsierdzia wywołanych przez VISA⁴².

W przypadku ciężkich zakażeń MRSA z MIC wankomycyny 1,5-2,0 μg/ml (tzw. hVISA), które nie odpowiadają na leczenie wankomycyną, należy rozważyć alternatywny lek (np. daptomycynę lub ceftarolinę)²⁴. Należy zachować ostrożność przy stosowaniu daptomycyny u pacjentów z MIC wankomycyny ≥1,0 μg/ml, szczególnie przy zmianie leczenia z wankomycyny, ze względu na wyższe wskaźniki niewrażliwości na daptomycynę i niepowodzeń klinicznych²⁴.

Podsumowanie i zalecenia praktyczne

Skuteczne leczenie zakażeń MRSA wymaga kompleksowego podejścia, obejmującego zarówno interwencje chirurgiczne, jak i odpowiednio dobrane antybiotyki. Kluczowe elementy skutecznej terapii to:

Wczesna diagnoza i rozpoczęcie leczenia⁴³
Drenaż ropni i czyszczenie ran w przypadku zakażeń skóry i tkanek miękkich⁵
Wybór antybiotyku na podstawie antybiogramu i lokalizacji zakażenia¹⁰
Odpowiedni czas trwania leczenia, zależny od rodzaju zakażenia⁹
Ukończenie pełnej zaleconej kuracji antybiotykowej, nawet po ustąpieniu objawów⁶
Regularne monitorowanie skuteczności leczenia²²
Rozważenie dekolonizacji u pacjentów z nawracającymi zakażeniami²⁵

Konsultacja ze specjalistą chorób zakaźnych jest zalecana u wszystkich pacjentów z bakteriemią S. aureus. Prowadzi to do lepszego przestrzegania wytycznych Infectious Diseases Society of America, zmniejszenia śmiertelności wewnątrzszpitalnej i wcześniejszego wypisu⁴⁴.

Interwencja farmaceuty w dawkowaniu wankomycyny wykazała poprawę wskaźników przeżycia w retrospektywnym badaniu pacjentów z bakteriemią MRSA⁴⁴. Takie interdyscyplinarne podejście może znacząco poprawić wyniki leczenia zakażeń MRSA.

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 MRSA: Treatment, causes, and symptoms
https://www.medicalnewstoday.com/articles/10634
MRSA is a common and potentially serious infection that has developed resistance to several types of antibiotics. These include methicillin and related antibiotics, such as penicillin, vancomycin, and oxacillin. This resistance makes MRSA difficult to treat. […] Although doctors can no longer use methicillin to treat MRSA, this does not mean that the infection is untreatable. Some antibiotics are effective in treating it. […] The type of treatment for MRSA will depend on the following factors: the type and location of the infection, the severity of the symptoms, the antibiotics to which the strain of MRSA responds. […] The bacteria that cause MRSA are resistant to some but not all antibiotics. A doctor will prescribe medication that is suitable for the particular infection that occurs. […] A person should make sure that they take the whole course of antibiotics exactly as the doctor prescribes. Some people stop taking the drugs after the symptoms disappear, but this can increase the risk of the infection coming back and becoming resistant to treatment.
#2 MRSA infection – Symptoms & causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/mrsa/symptoms-causes/syc-20375336
Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by a type of staph bacteria that’s become resistant to many of the antibiotics used to treat ordinary staph infections. […] MRSA infections can resist the effects of many common antibiotics, so they’re more difficult to treat. This can allow the infections to spread and sometimes become life-threatening. […] MRSA is the result of decades of often unnecessary antibiotic use. […] In the hospital, people who are infected or colonized with MRSA often are placed in isolation as a measure to prevent the spread of MRSA. […] Hospital rooms, surfaces and equipment, as well as laundry items, need to be properly disinfected and cleaned regularly. […] Careful hand washing remains your best defense against germs. […] Keep cuts and scrapes clean and covered with clean, dry bandages until they heal. […] MRSA spreads on infected objects as well as through direct contact.
#3 Methicillin-Resistant Staphylococcus aureus – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK482221/
Based on the antibiotic susceptibilities, Methicillin resistance in S. aureus is defined as an oxacillin minimum inhibitory concentration (MIC) of greater than or equal to 4 micrograms/mL. MRSA infection is one of the leading causes of hospital-acquired infections and is commonly associated with significant morbidity, mortality, length of stay, and cost burden. […] The selection of empiric antibiotic therapy for the treatment of MRSA infection depends on the type of disease, local S. aureus resistance patterns, availability of the drug, side effect profile, and individual patient profile. […] For most uncomplicated SSTIs suspected of MRSA infection, empirical treatment is with oral antibiotics like trimethoprim/sulfamethoxazole, tetracyclines, such as doxycycline or minocycline, and clindamycin. Higher doses of trimethoprim/sulfamethoxazole (160/800mg, one tablet three times daily or 2 tablets twice daily in adults) is recommended for MRSA in patients with normal renal function. Newer agents, such as linezolid and tedizolid, and delafloxacin also can be used as alternative oral regimens if available and deemed cost-effective.
#4 MRSA: Causes, Symptoms, Diagnosis, Treatment & Prevention
https://my.clevelandclinic.org/health/diseases/11633-methicillin-resistant-staphylococcus-aureus-mrsa
MRSA infections are hard to treat because very few antibiotics are effective against them. […] Providers treat MRSA infections by caring for open wounds and finding antibiotics that are effective against the strain of MRSA you have. Wound treatment includes draining fluid and surgically removing infected tissue. […] Antibiotics a provider might use to treat MRSA include: Vancomycin, Rifampin, Trimethoprim/sulfamethoxazole (TMP/SMX), Ceftaroline, Linezolid, Daptomycin, Clindamycin, Doxycycline, Delafloxacin. […] Sometimes, MRSA is called a superbug because its defense mechanisms against so many antibiotics make it hard to treat. One strategy providers might use is to treat you with more than one type of antibiotic at a time. […] If you have a skin infection, your provider will surgically treat and drain your wounds. They might give you topical or oral antibiotics. You’ll need to be treated in the hospital if you have a severe or invasive MRSA infection. […] Yes, more than half of all MRSA cases are cured with antibiotics, and providers successfully treat most MRSA skin infections. But serious infections like pneumonia, endocarditis and bacteremia can quickly get worse before a provider can find a treatment that works.
#5 MRSA infection – Diagnosis & treatment – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/mrsa/diagnosis-treatment/drc-20375340
Both health care-associated and community-associated strains of still respond to certain antibiotics. […] Doctors may need to perform emergency surgery to drain large boils (abscesses), in addition to giving antibiotics. […] In some cases, antibiotics may not be necessary. For example, doctors may drain a small, shallow boil (abscess) caused by rather than treat the infection with drugs.
#6 MRSA Diagnosis and Treatment: Antibiotics, Drainage, and More
https://www.webmd.com/skin-problems-and-treatments/understanding-mrsa-detection-treatment
MRSA is treatable. By definition, MRSA is resistant to some antibiotics. But other kinds of antibiotics still work. If you have a severe infection, or MRSA in the bloodstream, you will need intravenous antibiotics. […] Antibiotics, however, aren’t always necessary. If you have a small skin boil caused by MRSA, your doctor may just make an incision and drain it. […] If you are prescribed antibiotics, follow your health care provider’s instructions precisely. Never stop taking your medicine, even if you’re feeling better. If you don’t take all of your medicine, some of the staph bacteria may survive, requiring re-treatment. Inadequate treatment also increases the development of antibiotic resistance in the surviving staph population. If you still have staph you can infect someone else.
#7 Methicillin-resistant Staphylococcus aureus (MRSA) Basics | MRSA | CDC
https://www.cdc.gov/mrsa/about/index.html
Healthcare providers often prescribe antibiotics to treat MRSA infections. […] Some types of S. aureus infections need surgery to drain infected areas. Your healthcare provider will determine which treatments are best for you. While MRSA can be resistant to several antibiotics, meaning these drugs cannot cure the infections, there are antibiotics available to treat MRSA infections.
#8 Learning about MRSA: A guide for Patients – MN Dept. of Health
https://www.health.state.mn.us/diseases/staph/mrsa/book.html
Don’t do this yourself. It is very dangerous to squeeze or poke a skin infection because it can push the bacteria deeper into the skin and make the infection much worse. Your doctor will open the sore and drain it. After the infection is drained, you must keep it covered with a clean, dry bandage, until it heals. […] To decrease the amount of staph on your body your doctor may, for a short period of time: Tell you to shower daily with antibacterial soap, Prescribe antibiotic ointment to put in your nose for several days, Prescribe antibiotic pills (in some cases). […] Contact your doctor if: you have any new symptoms during or after treatment for a MRSA skin infection such as a new fever or a fever that won’t go away, the infection gets worse, the infection is not healing, the infection comes back, you have questions.
#9 How Long Does It Take for MRSA to Heal?
https://www.healthline.com/health/mrsa-healing-stages
The treatment for MRSA can vary depending on the stage of the infection: […] Treatment for mild skin infections can include taking antibiotics, such as trimethoprim-sulfamethoxazole (Bactrim), clindamycin, or doxycycline, for roughly 5-14 days. Treatment plans and their duration vary depending on a person’s medical needs and how the infection responds to treatment. Keeping any wound cleaned and dressed is also important for healing. […] For deeper skin infections or a systemic spread, intravenous antibiotics, hospitalization and sometimes surgery may be needed. […] MRSA infections without symptoms do not usually require treatment. An early stage skin infection is usually only treated with antibiotics and careful wound care, while a more severe infection will require intravenous antibiotics and possibly surgery. […] Depending on the severity of the infection, MRSA wounds can take from a few days to several months to heal. It’s important to work with your healthcare professional and complete a full course of treatment to properly heal a MRSA infection and prevent complications.
#10 Treatment for MRSA: What to know
https://www.medicalnewstoday.com/articles/mrsa-treatment
If doctors suspect methicillin-resistant Staphylococcus aureus (MRSA) is causing an infection, they will prescribe antibiotics to treat it. Some lab tests can determine the best antibiotic choice. Draining the wound can also help the tissue heal. […] MRSA is a type of bacteria that many antibiotics cannot easily kill. However, some antibiotics can treat the infection. Without treatment, an MRSA infection can be life threatening. […] Doctors treat MRSA with antibiotics. The type and dose of antibiotics may depend on the results of lab tests. […] Treatment duration can vary, but a typical course can last 5 to 14 days. A doctor may prescribe the following: clindamycin (Cleocin), minocycline (Minocin), doxycycline (Adoxa), trimethoprim-sulfamethoxazole (Bactrim). A combination of antibiotics may be necessary.
#11 Methicillin-Resistant Staphylococcus aureus – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK482221/
Intravenous vancomycin is the drug of choice for most MRSA infections seen in hospitalized patients. It can be used both as empiric and definitive therapy as most MRSA infections are susceptible to vancomycin. […] Daptomycin is a suitable parenteral alternative when vancomycin is not available or not being tolerated. Other short-acting options include ceftaroline and telavancin. Long-acting treatment options include dalbavancin and oritavancin. Regardless of the initial empiric antibiotic choice, subsequent therapy should be tailored based on the careful review of culture and susceptibility data. […] The duration of therapy for treatment of MRSA SSTIs may range from 5 to 14 days depending on the extent of infection and response to treatment. […] Vancomycin and daptomycin are considered adequate empiric therapy according to the Infectious Diseases Society of America guidelines of 2011.
#12 Methicillin-Resistant Staphylococcus Aureus (MRSA)
https://www.health.ny.gov/diseases/communicable/staphylococcus_aureus/methicillin_resistant/fact_sheet.htm
What is the treatment for MRSA? […] Although MRSA cannot be effectively treated with antibiotics such as methicillin, nafcillin, cephalosporin or penicillin, it can usually be treated with an antibiotic called vancomycin. Recently, however, a few strains of Staphylococcus aureus have even developed some degree of resistance to vancomycin. The vancomycin-resistant strains may be more difficult to treat. Newer antibiotics are being developed to address this problem.
#13 Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs | Bulletin of the National Research Centre | Full Text
https://bnrc.springeropen.com/articles/10.1186/s42269-023-01072-3
Methicillin-resistant Staphylococcus aureus (MRSA) is a common bacterial infection that is a significant source of illness and mortality globally. The ideal treatments for MRSA remain challenging, and the quest for new antibiotic targets and advanced drug delivery systems with safety profiles is necessary to ensure treating MRSA infections adequately in the future. This article primarily focuses on different therapeutic medications and their modes of action for general microbial infections and goes through the latest developments in novel drug delivery technologies, such as hydrogels, lipid particles, nanocarriers, and polymers for MRSA treatment. […] Vancomycin remains the most frequently used antibiotic in the therapy of MRSA. A new promising antibacterial therapeutic management system was introduced through the FDA to treat MRSA infection conditions, and the therapy management system is also used in different microbial resistance conditions. The FDA has permitted five anti-infective agents for treating MRSA-related multidrug resistance: linezolid, daptomycin, tigecycline, telavancin, and ceftaroline. Linezolid, one of the new antibiotic agents available in intravenous formulation, is still available in oral and intravenous preparations. This antibiotic could be used as a first-line treatment for beta-hemolytic streptococci and MRSA.
#14 Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics) – UpToDate
https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics/print
If MRSA infection is diagnosed, you will be given an antibiotic. There are now a large number of antibiotics that can be successfully used to treat MRSA infections. The antibiotic dose or type may be changed when the results of the laboratory culture are available. […] Treatment of MRSA at home usually includes a 7- to 10-day course of an antibiotic (by mouth) such as trimethoprim-sulfamethoxazole (brand name: Bactrim), clindamycin, minocycline, linezolid, or doxycycline. It is very important to carefully follow the instructions for taking the antibiotic; this means taking it on time and finishing the entire course of treatment. If the oral antibiotic is not effective or if the infection is making you ill, your doctor might try a different antibiotic instead, including administering antibiotics into your blood, or you may need to be treated in the hospital.
#15 Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics) – UpToDate
https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics
MRSA TREATMENT […] If MRSA infection is diagnosed, you will be given an antibiotic. There are now a large number of antibiotics that can be successfully used to treat MRSA infections. The antibiotic dose or type may be changed when the results of the laboratory culture are available. […] At home â Treatment of MRSA at home usually includes a 7- to 10-day course of an antibiotic (by mouth) such as trimethoprim-sulfamethoxazole (brand name: Bactrim), clindamycin, minocycline, linezolid, or doxycycline. It is very important to carefully follow the instructions for taking the antibiotic; this means taking it on time and finishing the entire course of treatment. If the oral antibiotic is not effective or if the infection is making you ill, your doctor might try a different antibiotic instead, including administering antibiotics into your blood, or you may need to be treated in the hospital.
#16 Methicillin-resistant Staphylococcus aureus – Wikipedia
https://en.wikipedia.org/wiki/Methicillin-resistant_Staphylococcus_aureus
Treatment of MRSA infection is urgent and delays can be fatal. The location and history related to the infection determines the treatment. The route of administration of an antibiotic varies. Antibiotics effective against MRSA can be given by IV, oral, or a combination of both, and depend on the specific circumstances and patient characteristics. The use of concurrent treatment with vancomycin or other beta-lactam agents may have a synergistic effect. […] Both CA-MRSA and HA-MRSA are resistant to traditional anti-staphylococcal beta-lactam antibiotics, such as cephalexin. CA-MRSA has a greater spectrum of antimicrobial susceptibility to sulfa drugs (like co-trimoxazole (trimethoprim/sulfamethoxazole), tetracyclines (like doxycycline and minocycline) and clindamycin (for osteomyelitis). MRSA can be eradicated with a regimen of linezolid, though treatment protocols vary and serum levels of antibiotics vary widely from person to person and may affect outcomes. The effective treatment of MRSA with linezolid has been successful in 87% of people. Linezolid is more effective in soft tissue infections than vancomycin. This is compared to eradication of infection in those with MRSA treated with vancomycin. Treatment with vancomycin is successful in approximately 49% of people. Linezolid belongs to the newer oxazolidinone class of antibiotics which has been shown to be effective against both CA-MRSA and HA-MRSA. The Infectious Disease Society of America recommends vancomycin, linezolid, or clindamycin (if susceptible) for treating those with MRSA pneumonia. Ceftaroline, a fifth-generation cephalosporin, is the first beta-lactam antibiotic approved in the US to treat MRSA infections in skin and soft tissue or community-acquired pneumonia.
#17 What’s new in the treatment of serious MRSA infection? – PubMed
https://pubmed.ncbi.nlm.nih.gov/25211361/
Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections. […] This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance. […] Ceftaroline and ceftobiprole are anti-MRSA cephalosporins and are noninferior to comparator agents in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and pneumonia. […] Tedizolid is more potent than linezolid, has improved pharmacokinetics and reduced toxicity and is active against cfr-containing S. aureus. […] Telavancin now has approval for treatment of hospital-acquired pneumonia, and recent phase 2 trial data showed similar cure rates in S. aureus bacteremia. […] Dalbavancin and oritavancin are administered once weekly and are noninferior to comparators for acute bacterial skin and skin structure infections. […] Several new MRSA-active agents are now approved for use, although much of the data is derived from treatment of acute bacterial skin and skin structure infections or pneumonia. […] Further studies are required for more invasive infections, such as bacteremia and endocarditis.
#18 IDSA Guidelines on the Treatment of MRSA Infections in Adults and Children | AAFP
https://www.aafp.org/pubs/afp/issues/2011/0815/p455.html
For hospitalized patients with complicated skin and soft-tissue infections (i.e., deeper soft-tissue infections, surgical or traumatic wound infection, major abscesses, cellulitis, or infected ulcers and burns), empiric therapy for MRSA should be considered pending culture results, in addition to surgical debridement and broad-spectrum antibiotics. […] Treatment for seven to 14 days is recommended, but should be individualized to the patient’s clinical response. […] In children with minor skin infections (e.g., impetigo) or secondarily infected lesions (e.g., eczema, ulcers, lacerations), treatment with mupirocin 2% topical cream (Bactroban) is recommended. […] Vancomycin is recommended in hospitalized children. […] Physicians should provide instructions on personal hygiene and wound care for patients with skin and soft-tissue infections.
#19 MRSA in adults: Treatment of skin and soft tissue infections | Time of Care
https://www.timeofcare.com/mrsa-in-adults-treatment-of-skin-and-soft-tissue-infections/
Oral Antibiotics to treat MRSA: Remember: BCD Bactrim, Clinda, and Doxy. Bactrim DS (160/800) po BID. Clindamycin 300 mg po three times per day. Doxycycline 100 mg po BID. Minocycline may also be used. Regardless of medication choice, treat for 5 to 10 days. Note: Clindamycin (300 to 450 mg every six to eight hours) has good activity against MRSA. Because Clinda comes in 150 or 300 tabs, I choose to go with 300 three times per day. Linezolid or tedizolid also come as po and have been shown to work just as effectively as vancomycin to treat MRSA skin infections. However, its too expensive and has toxicity. It should be reserved for those who do not respond to or cannot tolerate an older agent. The appropriate duration of therapy is one to two weeks; the clinical response to therapy should guide antibiotic duration. Clindamycin is FDA approved for the treatment of MRSA infections and is appropriate in infants. Trimethoprim/sulfamethoxazole is not FDA approved for MRSA infections, but most strains of the community-acquired bacteria are susceptible to this combination. It is safe to use in infants over the age of 2 months, but is not available as an intravenous preparation and may be inadequate if the infection turns out to be streptococcal.
#20 Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics) – UpToDate
https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics/print
In addition to antibiotics, your health care provider may drain the infected area by inserting a needle or making a small cut in the skin. This is done to reduce the amount of infected material (pus), which will help the tissue to heal. […] Hospitalized people with MRSA infections are usually treated with an intravenous medication. The intravenous antibiotic is usually continued until the person is improving. […] In many cases, the person will be given antibiotics after discharge from the hospital, either by mouth or by intravenous (IV). This may be needed for a short period of time or for as long as six to eight weeks. Intravenous antibiotics can be given at home, by a visiting nurse, or in a rehabilitation facility. […] In the hospital, if you are colonized but not infected with MRSA, you may be treated with mupirocin ointment and chlorhexidine soap.
#21 MRSA in adults: Treatment of skin and soft tissue infections | Time of Care
https://www.timeofcare.com/mrsa-in-adults-treatment-of-skin-and-soft-tissue-infections/
Vancomycin is the drug of choice. If you cant use Vanc, consult ID for help using one of the following: Vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose. Daptomycin Skin and soft tissue infection 4 mg/kg IV once daily. Bacteremia 6 mg/kg IV once daily. Linezolid 600 mg IV (or orally) twice daily. Ceftaroline 600 mg IV every 12 hours. Dalbavancin (for skin and soft tissue infection) Single-dose regimen: 1500 mg once. Two-dose regimen: initial dose 1000 mg, followed by 500 mg dose one week later. Oritavancin (for skin and soft tissue infection) 1200 mg IV as a single dose. Tedizolid (for skin and soft tissue infection) 200 mg IV (or orally) once daily. Telavancin 10 mg/kg once daily.
#22 Treatment of MRSA Infections | MDedge Internal Medicine
https://www.mdedge9-ma1.mdedge.com/internalmedicine/article/57845/treatment-mrsa-infections
IV vancomycin is recommended for the treatment of MRSA infections of the central nervous system, although linezolid and IV trimethoprim/sulfa are alternatives. […] Shunt removal (with replacement only after cerebrospinal fluid cultures remain sterile) and antimicrobials are recommended for CNS shunt infection. […] IV vancomycin should be dosed at 15-20 mg/kg (maximum dose, 2 g) of actual body weight every 8-12 hours in patients with normal renal function. […] Trough concentrations of 15-20 mcg/mL are recommended when vancomycin is used to treat serious MRSA infections.
#22 Treatment of MRSA Infections | MDedge Internal Medicine
https://www.mdedge9-ma1.mdedge.com/internalmedicine/article/57845/treatment-mrsa-infections
Outpatients with purulent cellulitis in the absence of a drainable abscess should be treated empirically for MRSA pending culture. […] Empirical antimicrobials for outpatient MRSA skin infections include clindamycin, trimethoprim-sulfa, a tetracycline, and linezolid. […] Hospitalized patients with complicated soft-tissue infections should be treated with surgical debridement and broad-spectrum antimicrobials, including empirical antimicrobials for MRSA, pending culture data. […] In addition to appropriate antibiotic treatment, adults with MRSA bacteremia should have echocardiographic evaluation for endocarditis, clinical assessment to look for other foci of infection, and repeat blood cultures 2-4 days following the initial set to assess for clearance of bacteremia. […] Vancomycin or daptomycin for a minimum of 2 weeks is recommended for treatment of uncomplicated bacteremia.
#23 MRSA Infection: Symptoms, Treatment, Causes & Pictures
https://www.emedicinehealth.com/mrsa_infection/article_em.htm
The majority of serious MRSA infections are treated with two or more antibiotics that, in combination, often still are effective against MRSA (for example, vancomycin, linezolid, rifampin, sulfamethoxazole and trimethoprim, and others). […] Minor skin infections, however, may respond well to topical mupirocin. The earlier the appropriate diagnosis and therapy are instituted for MRSA, the better the prognosis. […] Drainage of pus is the main surgical treatment for MRSA infections. Items that can serve as sources of infection (tampons, intravenous lines) should be removed. Other foreign bodies present that are likely sources of infection may need to be removed if appropriate antibiotic therapy is unsuccessful. Other areas that can harbor MRSA and may need surgical interventions are joint infections, postoperative abscesses, and infection of the bone. This is not an all-inclusive list; any site that continues to harbor MRSA and is not adequately treated by antibiotic therapy should be considered for surgical intervention. Drainage of pus needs to be followed by appropriate antibiotic therapy as discussed above.
#24 Staphylococcus aureus | Johns Hopkins ABX Guide
https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540518/all/Staphylococcus_aureus
In severely ill, or risk for MRSA, empiric coverage traditionally with vancomycin IV, although daptomycin, ceftaroline or linezolid among others would potentially service depending on the clinical presentation. […] For hospital-acquired staphylococcal bacteremia, most ID clinicians obtain echocardiography. Highly suggested for patients with ESRD or on hemodialysis, vertebral osteomyelitis, discitis or epidural abscess, intravascular or intracardiac device, prolonged bacteremia, 4d. […] Severe MRSA infections with vancomycin MIC 1.5-2.0 (so-called hVISA) not responding to vancomycin therapy, consider an alternative agent (e.g., daptomycin or ceftaroline). […] Vancomycin does have dose-related nephrotoxicity especially with maintaining 15-20 ug/mL troughs. […] Daptomycin: caution for use with vancomycin MIC 1.0, especially if switching from vancomycin therapy due to higher rates of non-susceptibility of daptomycin and clinical failures.
#25 IDSA Guidelines on the Treatment of MRSA Infections in Adults and Children | AAFP
https://www.aafp.org/pubs/afp/issues/2011/0815/p455.html
Decolonization may be considered if a patient develops a recurrent infection despite good personal hygiene and wound care, or if other household members develop infections. […] For adults with uncomplicated bacteremia, recommended treatment includes vancomycin or daptomycin at a dosage of 6 mg per kg intravenously once per day for at least two weeks. […] For adults with infective endocarditis, intravenous vancomycin or daptomycin (6 mg per kg intravenously once per day for six weeks) is recommended. […] Empiric therapy for MRSA is recommended, pending sputum and/or blood culture results, for hospitalized patients with severe community-acquired pneumonia. […] In children, intravenous vancomycin is recommended for treating MRSA pneumonia. […] The mainstay of therapy for osteomyelitis is surgical debridement with drainage of associated soft-tissue abscesses.
#26 Methicillin-Resistant Staphylococcus aureus – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK482221/
The 2015 American Heart Association (AHA) guidelines recommend intravenous vancomycin as the first line treatment for endocarditis. For patients who cannot tolerate vancomycin, intravenous daptomycin should be used. Recommended duration of treatment for native valve endocarditis is six weeks. […] However, there is no evidence of additional benefit of combining rifampin or gentamicin with vancomycin or daptomycin for native valve endocarditis.
#27 Treatment of MRSA Infections | MDedge Internal Medicine
https://www.mdedge9-ma1.mdedge.com/internalmedicine/article/57845/treatment-mrsa-infections
Complicated bacteremia and endocarditis should be treated parenterally for at least 4-6 weeks, in addition to debridement of any septic foci of infection. […] Empirical treatment for severe community-acquired pneumonia should include MRSA coverage, pending culture results. […] MRSA pneumonia, whether of community or health care facility origin, may be treated with IV vancomycin, linezolid [oral/IV] or clindamycin [oral/IV] in susceptible patients; antimicrobials should be continued for 7-21 days, depending on the patients response. […] Surgical debridement and drainage of infected tissues are mainstays of therapy for bone and joint infections. […] Concomitant antibiotic treatment is recommended for a minimum of 8 weeks for osteomyelitis, and for 3-4 weeks for native joint septic arthritis.
#28 IDSA Guidelines on the Treatment of MRSA Infections in Adults and Children | AAFP
https://www.aafp.org/pubs/afp/issues/2011/0815/p455.html
The optimal duration of therapy for MRSA osteomyelitis is unknown, although a minimum of eight weeks is recommended. […] The recommended treatment for patients with meningitis is intravenous vancomycin for two weeks. […] The role of cultures in managing recurrent skin and soft-tissue infections is limited. […] High-dose daptomycin (10 mg per kg per day), if the isolate is susceptible, in combination with another agent (e.g., gentamicin, rifampin, linezolid, TMP/SMX, a beta-lactam antibiotic) should be considered. […] For mild cases of pustulosis with localized disease, topical treatment with mupirocin may be adequate in full-term neonates and young infants. […] Recommended treatment of neonatal MRSA sepsis is intravenous vancomycin, with dosing as outlined in Red Book.
#29
#30 Long-Acting Anti-MRSA Agents: One Dose to Cure?
https://www.contagionlive.com/view/long-acting-anti-mrsa-agents-provide-one-dose-to-cure
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of both health care-associated and community-associated infections. The most common types of infections caused by MRSA are skin and soft-tissue infections, bacteremia, infective endocarditis, pneumonia, and osteomyelitis. Per current guidelines, oral antimicrobials for the treatment of mild-to-moderate MRSA skin infections include trimethoprim/sulfamethoxazole, clindamycin, doxycycline, minocycline, and linezolid. Alternatively, vancomycin tends to be the most common intravenous (IV) agent for empiric coverage of a potentially serious MRSA infection. Serious infections caused by MRSA have a high morbidity and mortality, with estimates for mortality as high as 30% to 37% with endocarditis. Treatment durations for MRSA infections can vary widely based on the site and source of infection. Because of growing resistance and the need for a single-dose treatment option to help patients avoid hospitalization, facilitate their earlier discharge, or eliminate their need for continued outpatient parenteral antimicrobial therapy (OPAT), long-acting anti-MRSA agents have been developed.
#31 Long-Acting Anti-MRSA Agents: One Dose to Cure?
https://www.contagionlive.com/view/long-acting-anti-mrsa-agents-provide-one-dose-to-cure
Regardless of the great potential these agents can provide, the ultimate future of oritavancin and dalbavancin is yet to be determined. Both the pharmacokinetics and the convenient 1-time dosing of these drugs make them alluring options for the treatment of gram-positive infections that otherwise require prolonged courses of antibiotics, such as osteomyelitis, endocarditis, and even bacteremia. However, recent literature searches mostly yield case reports of these drugs being used as alternative therapy for infections. […] In conclusion, dalbavancin and oritavancin are promising novel agents for the treatment of gram-positive organisms. Although they are currently FDA approved only for the treatment of ABSSIs, they have potential use in the treatment of other infections, such as osteomyelitis and endocarditis. However, further studies, including randomized controlled trials, are still needed.
#32 How Light Turns Hydrogen Peroxide into a MRSA Treatment | The Brink | Boston University
https://www.bu.edu/articles/2019/blue-light-therapy-mrsa-treatment/
Boston University engineers have invented a new blue light therapy that can kill MRSA without antibiotics. Their technique, which they are preparing to take into a clinical trial, uses phototherapy and hydrogen peroxide to kill 99.9 percent of antibiotic-resistant bacteria. Boston University College of Engineering researchers who invented the technique say they have shown, experimentally, it can kill 99.9 percent of methicillin-resistant Staphylococcus aureus, known as MRSA. When hydrogen peroxide is delivered in combination with blue light, it’s able to flood the insides of MRSA cells and cause them to biologically implode, eradicating 99.9 percent of bacteria. Perhaps what’s most promising is that blue light phototherapy doesn’t affect healthy cells of the body, so the technique could be used to treat MRSA infections without harming any surrounding tissue or skin. Partnering with Purdue University microbiologists and researchers at the Massachusetts General Hospital Wellman Center for Photomedicine, the group analyzed the therapy’s effectiveness in mice and observed that the blue light plus hydrogen peroxide treatment was able to speed healing of skin wounds infected with MRSA. Now, Cheng’s lab is teaming up with David Negron, a foot surgeon at Boston Medical Center and instructor of surgery at BU School of Medicine, to develop a clinical trial evaluating the technique’s ability to treat patients with diabetic ulcers. If we can treat diabetic ulcers, that will change people’s lives, Cheng says.
#33 Treatment of MRSA-infected osteomyelitis using bacterial capturing, magnetically targeted composites with microwave-assisted bacterial killing | Nature Communications
https://www.nature.com/articles/s41467-020-18268-0
Owing to the poor penetration depth of light, phototherapy, including photothermal and photodynamic therapies, remains severely ineffective in treating deep tissue infections such as methicillin-resistant Staphylococcus aureus (MRSA)-infected osteomyelitis. Here, we report a microwave-excited antibacterial nanocapturer system for treating deep tissue infections that consists of microwave-responsive Fe3O4/CNT and the chemotherapy agent gentamicin (Gent). This system, Fe3O4/CNT/Gent, is proven to efficiently target and eradicate MRSA-infected rabbit tibia osteomyelitis. Its robust antibacterial effectiveness is attributed to the precise bacteria-capturing ability and magnetic targeting of the nanocapturer, as well as the subsequent synergistic effects of precise microwaveocaloric therapy from Fe3O4/CNT and chemotherapy from the effective release of antibiotics in infection sites. The advanced target-nanocapturer of microwave-excited microwaveocaloric-chemotherapy with effective targeting developed in this study makes a major step forward in microwave therapy for deep tissue infections.
#34 Treatment of MRSA-infected osteomyelitis using bacterial capturing, magnetically targeted composites with microwave-assisted bacterial killing | Nature Communications
https://www.nature.com/articles/s41467-020-18268-0
An active bacteria-targeting nanocapturer with controlled release of antibiotics in particular not only reduces the toxicity of antibiotics but also improves therapeutic effects for bacterial infections. […] Here we report a dual-targeting and MV-excited drug release system for the synergistic eradication of MRSA-induced osteomyelitis using a combined microwaveocaloric-chemotherapy (MCCT) system. […] The final nanocomposites (Fe3O4/CNT/Gent) rapidly and efficiently eradicated MRSA-induced osteomyelitis by capturing the bacteria and enabling the MCCT to subsequently kill it in combination with magnetic targeting. This strategy is promising for improving the penetration of microwaveocaloric sensitizers and enhancing bacteria-specific synergistic therapies. […] The CNT displayed on the nanocapturer potently captured MRSA. When microwave-excited, the nanocapturers of Fe3O4/CNT are activated to generate thermal energy, which can locally melt PCM (the melting point is ~40C) and then locally release drug (Gent) at the site of the osteomyelitis with MRSA infection, finally eradicating MRSA precisely by combined the MCCT and an external magnetic field.
#35 Researchers explore promising treatment for MRSA âsuperbugâ | Cornell Chronicle
https://news.cornell.edu/stories/2021/09/researchers-explore-promising-treatment-mrsa-superbug
A new Cornell study has found the antimicrobial properties of certain stem cell proteins could offer a potential treatment to reduce infection in skin wounds. […] Treating wounds with the secretion of a type of stem cell effectively reduced the viability of methicillin-resistant Staphylococcus aureus better known as MRSA according to a new study from researchers at the Baker Institute for Animal Health, part of the College of Veterinary Medicine (CVM). […] The study may point to a possible new approach for treating MRSA. […] The findings contribute to the understanding of the MSC secretomes antimicrobial properties and further support the value of MSC secretome-based treatments for infected wounds. […] By identifying additional effective treatments, she said, we can contribute to reducing the use of antibiotics in both veterinary and human medicine, which is important for the fight against antibiotic resistance.
#36 Can you get rid of MRSA completely?
https://www.medicinenet.com/can_you_get_rid_of_mrsa_completely/article.htm
An individual may get rid of MRSA completely by following the prescription given by doctors. […] Yes, an individual may get rid of MRSA completely by following the prescription given by doctors strictly. MRSA can be treated with powerful antibiotics, nose ointments, and other therapies. […] Incision and drainage remain the primary treatment option for MRSA related skin infections. Additional treatment with antibiotics may depend on clinical assessment. Vancomycin or daptomycin are the agents of choice for the treatment of invasive MRSA infections. […] Vancomycin is considered to be one of the powerful antibiotics which is usually used in treating MRSA. However, this drug is slow on acting on bacteria. Some bacteria may also get resistant to this drug. […] As per research, a combo of three drugs or antibiotics may kill deadly staph infections. These antibiotics include meropenem, piperacillin, and tazobactam. These are from a class of antibiotics called beta-lactams that are not effective if given individually, however a combination of these three drugs is said to destroy MRSA. The researchers also found that these drugs did not produce any other genetic change in MRSA bacteria.
#37 Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs | Bulletin of the National Research Centre | Full Text
https://bnrc.springeropen.com/articles/10.1186/s42269-023-01072-3
Despite the commitment of several years, work has centered on improving the treatment of MRSA with a focus on increased activity and efficacy. The increased effects result from their size, structure, and protective inner environment, and the nanosubstance improves drug action in cell sites, organs, and tissues.
#38 MRSA infection in the community
https://www.health.wa.gov.au/Articles/J_M/Management-of-CA-MRSA
CA-MRSA strains, like all MRSA, are resistant to most beta-lactam antibiotics. […] Incision and drainage (ID) is recommended as a priority, when applicable. […] Prescribe antibiotics if ID is not possible, when there is cellulitis; they are febrile or systemically unwell. […] Management in a hospital is likely to be required for patients with large or deep abscesses, extensive cellulitis, or who are unwell with systemic symptoms. […] Decolonisation is the process of eradicating or reducing asymptomatic carriage of MRSA. […] The decision to recommend decolonisation should follow an assessment of the individual that includes their willingness and capability to comply with the regimen. […] The choice of antibiotics is dependent on the age, allergy history and co-morbidities of the patient. […] Clindamycin should NOT be used for MRSA isolates RESISTANT to erythromycin and related macrolide class antibiotics.
#39 Decolonisation treatment for people with MRSA
https://www.healthywa.wa.gov.au/Articles/A_E/Decolonisation-treatment-for-people-with-MRSA
Decolonisation is when topical treatments are used to try and get rid of methicillin resistant staphylococcus aureus (MRSA). […] It involves the use of an antiseptic body wash and nasal ointment for 5 days. […] Decolonisation treatment can reduce the risk of recurrent MRSA infections or spreading MRSA to others. […] Decolonisation can reduce the risk of you getting recurrent infections or spreading the MRSA to others who share the same household. […] Recommended MRSA nasal ointment and antiseptics: nasal ointment mupirocin 2 per cent (Bactroban) this is available by prescription from your doctor […] antiseptic body wash (triclosan 1 per cent or chlorhexidine 4 per cent) available over-the-counter at a pharmacy. […] How to use the nasal ointment apply twice a day for 5 days […] How to use the body wash use once a day for 5 days.
#40 MRSA. Methicillin (meticillin) resistant Staphylococcus aureus
https://dermnetnz.org/topics/methicillin-resistant-staphylococcus-aureus
The following steps are used for treatment of carriers of MRSA: Topical application of an antibiotic ointment such as mupirocin or fusidic acid to the nostrils, 23 times per day for 35 days. Antibacterial soaps and hand rubs. […] Treatment of active infection involves drainage of pus from furuncles and abscesses, and antibiotics. The antibiotic of choice for an infected inpatient is vancomycin given intravenously. Daptomycin is an alternative IV antibiotic. Oral clindamycin may be used in minor soft tissue infections in outpatients. […] These antibiotics are no better than flucloxacillin in the treatment of usual type S aureus, but are much more effective in MRSA infections. Other antibiotics are less effective and are used if there is resistance to vancomycin/clindamycin or in case of adverse reactions to these drugs. […] In life-threatening infections such as infective endocarditis, multiple antibiotics are often prescribed simultaneously (eg vancomycin plus an aminoglycoside plus rifampicin).
#41 Treatment of Meticillin-resistant Staphylococcus aureus (MRSA)
https://www.gloshospitals.nhs.uk/your-visit/patient-information-leaflets/treatment-of-meticillin-resistant-staphylococcus-aureus-mrsa/
This page gives you information about Meticillin-resistant Staphylococcus aureus (MRSA) and its treatment. […] How do you treat MRSA? […] The best way to treat and reduce the amount of MRSA on your skin is with a combination of prescribed lotions. These will reduce the number of germs on your skin. […] Known as mupirocin or Bactroban must be put inside your nostrils 3 times a day for the first 5 days of treatment. […] An antimicrobial body wash will also be prescribed. […] The purpose of treatment with the nasal cream and antimicrobial body wash is to reduce the MRSA on the skin during your time in hospital. The treatment will also lower the risk of an infection. […] These products must be used together for 5 days. If you are still a patient in hospital after this time, we will ask you to continue to wash with the antimicrobial body wash for the rest of your inpatient stay. […] Not necessarily. Some patients do remove the germs from the skin, while others do not get rid of them all. It is not known why this happens, but success often depends on how well you follow the advice on this page on how to apply the body wash and nasal ointment.
#42 Methicillin-resistant Staphylococcus aureus – Wikipedia
https://en.wikipedia.org/wiki/Methicillin-resistant_Staphylococcus_aureus
Vancomycin and teicoplanin are glycopeptide antibiotics used to treat MRSA infections. Teicoplanin is a structural congener of vancomycin that has a similar activity spectrum but a longer half-life. Because the oral absorption of vancomycin and teicoplanin is very low, these agents can be administered intravenously to control systemic infections. Treatment of MRSA infection with vancomycin can be complicated, due to its inconvenient route of administration. Moreover, the efficacy of vancomycin against MRSA is inferior to that of anti-staphylococcal beta-lactam antibiotics against methicillin-susceptible S. aureus (MSSA). […] Several newly discovered strains of MRSA show antibiotic resistance even to vancomycin and teicoplanin. Strains with intermediate (48 g/ml) levels of resistance, termed glycopeptide-intermediate S. aureus (GISA) or vancomycin-intermediate S. aureus (VISA), began appearing in the late 1990s. The first identified case was in Japan in 1996, and strains have since been found in hospitals in England, France, and the US. The first documented strain with complete (16 g/ml) resistance to vancomycin, termed vancomycin-resistant S. aureus (VRSA), appeared in the United States in 2002. […] Current guidelines recommend daptomycin for VISA bloodstream infections and endocarditis.
#43 MRSA Treatment, MRSA Symptoms, MRSA Causes – Dr. Axe
https://draxe.com/health/mrsa-treatment/
However, due to concerns over antibiotics and antibiotic resistance, doctors are hesitant to prescribe these medications unless completely necessary. […] When antibiotics are used to treat staph infections, drugs can include cephalosporins, nafcillin, sulfa drugs or vancomycin. […] MRSA has been shown to be resistant to at least several types of antibiotics, however. […] This is exactly why preventing MRSA from spreading globally is now an urgent matter. […] The CDC warns that finding infections early and getting care right away provide the best chance a patient has of controlling the infection, since intervention in the early stages prevents infections from becoming severe. […] When an infection does occur, natural MRSA treatment to help control staph infection symptoms include reducing fevers naturally, alleviating joint pain with mild heat and stretching, consuming immunity-boosting supplements, and treating skin rashes with natural products and/or essential oils.
#44 Staphylococcal Infections Treatment & Management: Medical Care, Surgical Care, Consultations
https://emedicine.medscape.com/article/228816-treatment
Consultation with an infectious disease specialist should be obtained for all patients with S aureus bacteremia. Doing so results in improved adherence to IDSA guidelines, decreased in-hospital mortality, and earlier discharge. Pharmacist intervention through vancomycin dosing has been shown to improve survival rates in a retrospective study of patients with MRSA bacteremia.